Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Descriptor ID |
D009190
|
MeSH Number(s) |
C15.378.190.625
|
Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 4 | 0 | 4 |
1997 | 1 | 0 | 1 |
1999 | 2 | 1 | 3 |
2000 | 1 | 0 | 1 |
2001 | 3 | 0 | 3 |
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 3 | 0 | 3 |
2005 | 2 | 0 | 2 |
2007 | 1 | 0 | 1 |
2009 | 2 | 0 | 2 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2015 | 0 | 1 | 1 |
2017 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2020 | 3 | 0 | 3 |
2021 | 2 | 0 | 2 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
-
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplant Cell Ther. 2021 11; 27(11):923.e1-923.e12.
-
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther. 2021 11; 27(11):921.e1-921.e10.
-
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2021 01; 27(1):68.e1-68.e9.
-
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2020 11; 26(11):2139-2146.
-
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020 05 07; 135(19):1696-1703.
-
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020 04; 61(4):940-943.
-
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Rev Hematol. 2018 07; 11(7):577-586.
-
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 06 26; 10(1):131.
-
?-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q). Cancer Res. 2017 08 01; 77(15):4116-4126.